When did Arbutus Biopharma Corporation report Q4 2024 earnings?

Arbutus Biopharma Corporation (ABUS) reported Q4 2024 earnings on March 27, 2025 before market open.

What were Arbutus Biopharma Corporation's Q4 2024 revenue and EPS?

Arbutus Biopharma Corporation reported revenue of $1.6M and diluted EPS of $-0.07 for Q4 2024.

Did Arbutus Biopharma Corporation beat estimates in Q4 2024?

Revenue missed the consensus estimate of $2.3M by $683.0K. EPS beat the consensus estimate of $-0.08 by $0.01.

Where can I find Arbutus Biopharma Corporation's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001447028-25-000083) directly on SEC EDGAR. The filing index links above go to sec.gov.

Arbutus Biopharma Corporation ABUS Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

Revenue$1.6MMiss by $683.0K Diluted EPS-$0.07Beat by $0.01

Revenue estimate$2.3M

EPS estimate-$0.08

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$700.0K

EPS estimate-$0.02

Financials

Q4 2024

Income statement

See full

Revenue$1.6M-26.6%

Operating income-$13.9M+32.8%

Net income-$12.5M+35.1%

EPS (diluted)-$0.07+41.7%

Balance sheet

See full

Cash & equivalents$36.3M+38.2%

Total debt$1.3M-27.1%

Total equity$97.4M-8.2%

Total assets$131.7M-8.8%

Cash flow

See full

Operating cash flow-$10.3M+40.3%

CapEx$86.0K—

Free cash flow-$10.4M+39.9%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$619.64M+47.8%

Enterprise value$584.6M+48.1%

P/S100.4×+77.3×

Profitability

See full

Operating margin-1,236.7%-2,654pp

Net margin-1,133%-2,512pp

FCF margin-1,053.8%-6,354pp

Returns & leverage

See full

Return on equity-68.8%+11.8pp

Debt / equity0×0.0×

Current ratio8.2×+2.3×

Segments

By product

See full

Collaborations and licenses$1.1M—

Revenue from collaborations and licenses$581.0K+65.5%

Non-cash royalty revenue$516.0K-57.0%

By segment

See full

Reportable Segment$1.6M-65.3%

Versus estimates

Revenue

Q1 2026$179.1MBeat by $178.4M Q4 2025$1.1MBeat by $436.5K Q3 2025$529.0KMiss by $312.0K Q2 2025$10.7MBeat by $9.1M Q1 2025$1.8MMiss by $477.9K

Q4 2024$1.6MMiss by $683.0K

Diluted EPS

Q1 2026$0.87Beat by $0.90 Q4 2025-$0.01Beat by $0.03 Q3 2025-$0.04Beat by $0.02 Q2 2025$0.01Beat by $0.03 Q1 2025-$0.13Miss by $0.04

Q4 2024-$0.07Beat by $0.01

Ask the moment Arbutus Biopharma Corporation reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Arbutus Biopharma Corporation report Q4 2024 earnings?: Arbutus Biopharma Corporation (ABUS) reported Q4 2024 earnings on March 27, 2025 before market open.
What were Arbutus Biopharma Corporation's Q4 2024 revenue and EPS?: Arbutus Biopharma Corporation reported revenue of $1.6M and diluted EPS of $-0.07 for Q4 2024.
Did Arbutus Biopharma Corporation beat estimates in Q4 2024?: Revenue missed the consensus estimate of $2.3M by $683.0K. EPS beat the consensus estimate of $-0.08 by $0.01.
Where can I find Arbutus Biopharma Corporation's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001447028-25-000083) directly on SEC EDGAR. The filing index links above go to sec.gov.